IDD594

IDD594 is an experimental small molecule inhibitor of human aldose reductase, an enzyme implicated in the development of diabetic complications such as neuropathy and nephropathy. Structurally, it is a phenoxyacetic acid derivative with the chemical formula C16H12BrF2NO3S and a molecular weight of approximately 416.2 g/mol[1][2][3]. The compound has been studied in high-resolution X-ray crystallography and computational docking studies for its binding to aldose reductase[4][5][6]. Its mechanism involves competitive inhibition at the active site of aldose reductase, thereby reducing the conversion of glucose to sorbitol—a pathway associated with diabetic tissue damage[4][6]. While preclinical studies have demonstrated efficacy in improving diabetic complications, there are no approved indications or advanced clinical trials reported for this compound[1].

Other names

{2-[(4-bromo-2-fluorobenzyl)carbamothioyl]-5-fluorophenoxy}acetic acid[2-(4-bromo-2-fluoro-benzylthiocarbamoyl)-5-fluoro-phenyloxy]-acetic acid